DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

668 Mason BJ. Acamprosate and naltrexone treatment for alcohol
dependence: An evidence-based risk benefits assessment. Eur
Neuropsychopharmacol, 2003, 13:469–475.
McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence,
a chronic medical illness: Implications for treatment, insurance,
and outcomes evaluation. JAMA, 2000, 13:1689–1695.
McLellan AT, Woody GE, O’Brien CP. Development of psychiatric
illness in drug abusers: Possible role of drug preference.
N Engl J Med, 1979, 301:1310–1314.
Mendelson JH, Mello NK. Medical progress: Biologic concomitants
of alcoholism. N Engl J Med, 1979, 301:912–921.
O’Brien CP. Treatment of alcoholism as a chronic disorder. EXS,
1994, 71:349–359.
Peroutka SJ. 5-Hydroxytryptamine receptor interactions of
d-lysergic acid diethylamide. In, 50 Years of LSD: Current
status and Perspectives of Hallucinogens. (Pletscher A,
Ladewig D, eds.) Parthenon Publishing, New York, 1994, pp.
19–26.
Pettinati HM, O’Brien CP, Rabinowitz AR, et al. The status of
naltrexone in the treatment of alcohol dependence: Specific
effects of heavy drinking. J Clin Psychopharmacol, 2006,
26:610–615.
Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity
and genetic moderators of medication response: A doubleblind
placebo-controlled study. Arch Gen Psychiatry, 2007;
64:1069–1077.
Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics
and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine
(MDMA, “ecstasy”). Toxicol Lett,
2000, 112–113:143–146.
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors
on dopamine transporters are related to self-administration of
cocaine. Science, 1987, 237:1219–1223.
SECTION II
NEUROPHARMACOLOGY
Robinson GM, Sellers EM, Janecek E. Barbiturate and hypnosedative
withdrawal by a multiple oral phenobarbital loading
dose technique. Clin Pharmacol Ther, 1981, 30:71–76.
Satel SL, Southwick SM, Gawin FH. Clinical features of cocaineinduced
paranoia. Am J Psychiatry, 1991, 148:495–498.
Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal
syndrome after the double-blind cessation of caffeine consumption.
N Engl J Med, 1992, 327:1109–1114.
Srivastava ED, Russell MA, Feyerabend C, et al. Sensitivity
and tolerance to nicotine in smokers and nonsmokers.
Psychopharmacology, 1991, 105:63–68.
Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence
implicates the brain 5-HT 2
receptor as a site of action for LSD
and phenylisopropylamine hallucinogens. Psychopharmacology,
1988, 94:213–216.
Trujillo KA, Akil H. Inhibition of morphine tolerance and
dependence by the NMDA receptor antagonist MK-801.
Science, 1991, 251:85–87.
Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights
from imaging studies. J Clin Invest 2003, 111:1444–1451.
Weddington WW, Brown BS, Haertzen CA, et al. Changes in
mood, craving, and sleep during short-term abstinence reported
by male cocaine addicts. A controlled residential study. Arch
Gen Psychiatry, 1990, 47:861–868.
Wilhelmsen KC, Schuckit M, Smith TL. The search for genes
related to a low-level response to alcohol determined by alcohol
challenges. Alcohol Clin Exp Res, 2003, 27:1041–1047.
Williams KE, Reeves KR, Billing CB, et al. A double-blind study
evaluating the long-term safety of varenicline for smoking cessation.
Curr Med Res Opin, 2007, 23:793–801.